Insights
Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, has
Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon”), a biotechnology company focused on developing psychedelic medicines to treat addiction, and Silo Wellness Inc.
Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced
Launch of Psychedelics DNA Test Kit Phase 1 clinical trial for DMT progressing as planned Pre-clinical In Vivo work scheduled to start at Israeli CRO
HaluGen’s DNA genetic testing provides insights into the sensitivity and risks associated with psychedelic-assisted psychotherapy Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (“Entheon” or the
Exclusive Content
Gold’s rise sparks geopolitical risks and innovation in recycling gold from e-waste…
Explore the United States’ current parallels with the collapse of the Roman Empire… from similar economic challenges and social issues, the American Empire is being tested.
Andy Schectman believes the silver market is heavily manipulated…
For well over a century, gold stocks have been one of the most popular investment assets
among speculators. An essential fact sometimes ignored is that gold equities often drastically…
Authors for PinnacleDigest.com are not registered broker-dealers or financial advisors. Before investing in any securities, you should consult with your financial advisor and a registered broker-dealer. Never make an investment based solely on what you read on PinnacleDigest.com. As with all investments, an investor should carefully consider his investment objectives and risk tolerance before investing. Use of this Site constitutes acceptance of our Terms of Use, Privacy Policy and Disclosure & Compensation. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Pinnacle Digest.
Securities covered in articles on this website are highly speculative. When investing in speculative stocks of this nature, it is possible to lose your entire investment over time or even quickly. These are not suitable investments for most investors.
All statements in articles on this website are to be checked and verified by the reader. Articles on this website may contain technical or other inaccuracies, omissions, or typographical errors for which PinnacleDigest.com assumes no responsibility.
Please be aware and note the date in which articles are published on this website. As a result of the passing of time, the relevancy of the opinions and facts in articles are likely to diminish over time and may change without an update to the articles. As such, you cannot rely on the accuracy and timeliness of the information provided and should consider many of the articles irrelevant after an extended period of time from the date which it was published. Since there is no specific guideline as to how long an article may remain relevant, you should consider that all articles may be irrelevant shortly after they are published. This is especially true for articles that include information on publicly traded companies.
2024 © Pinnacle Digest. All rights reserved | Privacy Policy | Disclosure & Compensation | Terms of Use
Subscribe to our free newsletter for a weekly dose of the stories that move markets, and much more.
* By submitting your email you will receive our best content in your inbox weekly, which sometimes includes information about our sponsors. And you also agree to our Terms of Use and Privacy Policy.
